Hypothesis

Transient senescent fibroblasts secrete a matrix‑anchored latent TGF‑β1 isoform that remains sequestered in the extracellular matrix until mechanical strain triggers its activation, thereby acting as a temporary brake on fibroblast‑to‑myofibroblast conversion during the early phase of wound repair. With prolonged senescence, MMP‑14 (MT1‑MMP) cleaves the latent TGF‑β binding protein (LTBP‑1) within the SASP, liberating soluble TGF‑β1 and converting the secretome into a pro‑fibrotic signal that sustains myofibroblast activity and matrix deposition.

Core Mechanistic Insight

• The matrix‑bound isoform is characterized by a covalently linked LTBP‑1‑TGF‑β1 complex that resists proteolysis and requires integrin‑αVβ3‑mediated tensile force for release.
• MMP‑14 preferentially cleaves the hinge region of LTBP‑1, a modification absent in the transient SASP but enriched in chronic senescent fibroblasts.
• Loss of the anchored complex shifts TGF‑β signaling from a transient, context‑dependent pulse to a sustained, autocrine loop that drives SMAD2/3‑dependent transcription of COL1A1 and ACTA2.

Testable Predictions

1. In young mice subjected to a full‑thickness dermal wound, fibroblast‑specific Mmp14 knockout will retain higher levels of matrix‑bound TGF‑β1 (measured after acid‑soluble extraction) and display reduced α‑SMA+ myofibroblast density at day 5 post‑injury, without altering senescent cell frequency as assessed by p16^Ink4a^ reporter.
2. Early (0‑48 h) intermittent navitoclax treatment in wild‑type wounded mice will deplete the nascent senescent fibroblast pool, causing a measurable drop in matrix‑bound TGF‑β1 and a concomitant rise in soluble TGF‑β1, leading to exaggerated collagen deposition at day 14 that can be normalized by topical application of recombinant LTBP‑1‑TGF‑β1 complex.
3. In aged mice or in a model of chronic fibrosis (bleomycin‑induced lung injury), exogenous delivery of the LTBP‑1‑TGF‑β1 complex will restore the matrix‑bound fraction, suppress SMAD2/3 nuclear phosphorylation, and reduce hydroxyproline content even when senolytic clearance (dasatinib + quercetin) is administered.

Experimental Design

• Model 1: Fibroblast‑specific Cre‑ER (Fsp1‑CreER) crossed with Mmp14^fl/fl^ mice; tamoxifen induction 5 days before dorsal skin wounding. Groups: (a) vehicle, (b) intermittent navitoclax (days 1,3,5). Readouts at days 3,5,7,14: immunofluorescence for p16, α‑SMA, collagen I; sequential extraction ELISA for matrix‑bound vs soluble TGF‑β1; wound area planimetry.
• Model 2: Aged (20‑month) mice with identical wounding; groups receive (a) vehicle, (b) senolytic (dasatinib + quercetin) on days 2,4,6, (c) senolytic + LTBP‑1‑TGF‑β1 complex (10 µg cm⁻² daily), (d) LTBP‑1‑TGF‑β1 complex alone. Endpoints: lung collagen content, TGF‑β signaling readouts (p‑SMAD2/3 Western), senescence burden (SA‑β‑gal).
• Model 3: In‑vitro human fibroblast senescence induced by irradiation; conditioned media fractionated by heparin‑sepharose to isolate matrix‑bound TGF‑β1; assess effect on TGF‑β receptor activation in naïve fibroblasts using luciferase reporter.

Falsifiability If fibroblast‑specific Mmp14 loss does not change the matrix‑bound/TGF‑β1 ratio, or if early senolytic depletion fails to increase soluble TGF‑β1 and exacerbate fibrosis, the hypothesis is disproven. Conversely, a consistent shift toward the soluble isoform upon MMP‑14 activity or senolytic removal of transient senescent cells, coupled with rescue by exogenous matrix‑bound TGF‑β1, would validate the proposed mechanism.

References Transient pro‑regenerative SASP in fibroblasts [1]; senescence‑mediated tumor suppression [2]; developmental senescence driving remodeling [3]; chronic fibroblast senescence impairing healing [4]; paracrine senescence transmission via NF‑κB [5]; intermittent senolytic dosing preserving regeneration [6]